References
- Teo ZL, Tham YC, Yu M, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128:1580–1591. doi:10.1016/j.ophtha.2021.04.027.
- Tsai IT, Wu CC, Hung WC, et al. FABP1 and FABP2 as markers of diabetic nephropathy. Int J Med Sci. 2020;17:2338–2345. doi:10.7150/ijms.49078.
- Shaikh NF, Vohra R, Balaji A, et al. Role of optical coherence tomography-angiography in diabetes mellitus: utility in diabetic retinopathy and a comparison with fluorescein angiography in vision threatening diabetic retinopathy. Indian J Ophthalmol. 2021;69:3218–3224. doi:10.4103/ijo.IJO_1267_21.
- Mehta K, Behl T, Kumar A, Uddin MS, Zengin G, Arora S. Deciphering the neuroprotective role of glucagon-like peptide-1 agonists in diabetic neuropathy: current perspective and future directions. Curr Protein Pept Sc. 2021;22:4–18. doi:10.2174/1389203721999201208195901.
- Yeboah J, Erbel R, Delaney JC, et al. Development of a new diabetes risk prediction tool for incident coronary heart disease events: the multi-ethnic study of atherosclerosis and the Heinz Nixdorf recall study. Atherosclerosis. 2014;236:411–417. doi:10.1016/j.atherosclerosis.2014.07.035.
- Yau J, Rogers S, Kawasaki R. For the meta-analysis for eye disease (META-EYE) study group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556–564. doi:10.2337/dc11-1909.
- Chatziralli I, Theodossiadis G, Dimitriou E, Theodossiadis P. Evaluation of morphological characteristics of diabetic macular edema in patients with non-proliferative versus proliferative diabetic retinopathy: a spectral-domain optical coherence tomography study. Int Ophthalmol. 2021;41:2417–2424. doi:10.1007/s10792-021-01796-z.
- Dehdashtian E, Mehrzadi S, Yousefi B, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 2018;193:20–33. doi:10.1016/j.lfs.2017.12.001.
- Ola MS, Alhomida AS, Ferrario CM, Ahmad S. Role of tissue renin-angiotensin system and the chymase/angiotensin-(1-12) axis in the pathogenesis of diabetic retinopathy. Curr Med Chem. 2017;24:3104–3114. doi:10.2174/0929867324666170407141955.
- Sorrentino FS, Matteini S, Bonifazzi C, Sebastiani A, Parmeggiani F. Diabetic retinopathy and endothelin system: microangiopathy versus endothelial dysfunction. Eye (Lond). 2018;32:1157–1163. doi:10.1038/s41433-018-0032-4.
- Song HB, Jun HO, Kim JH, Yu YS, Kim KW, Kim JH. Suppression of protein kinase C-ζ attenuates vascular leakage via prevention of tight junction protein decrease in diabetic retinopathy. Biochem Bioph Res Co. 2014;444:63–68. doi:10.1016/j.bbrc.2014.01.002.
- Kennedy L, Baynes JW. Non-enzymatic glycosylation and the chronic complications of diabetes: an overview. Diabetologia. 1984;26:93–98. doi:10.1007/BF00281113.
- Yang Y, Liu Y, Li Y, et al. MicroRNA-15b targets VEGF and inhibits angiogenesis in proliferative diabetic retinopathy. J Clin Endocrinol Metab. 2020;105:3404–3415. doi:10.1210/clinem/dgaa538.
- Zang J, Guan G. Study of pigment epithelium-derived factor in pathogenesis of diabetic retinopathy. Eye Sci. 2015;30:81–88.
- Zhang SX, Wang JJ, Gao G, Parke K, Ma JX. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol. 2006;37:1–12. doi:10.1677/jme.1.02008.
- Chen H, Zhang X, Liao N, Wen F. Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy. Bmc Ophthalmol. 2017;17:176. doi:10.1186/s12886-017-0572-6.
- Wei J, Jiang H, Gao H, Wang G. Blocking mammalian target of rapamycin (mTOR) attenuates HIF-1α pathways engaged-vascular endothelial growth factor (VEGF) in diabetic retinopathy. Cell Physiol Biochem. 2016;40:1570–1577. doi:10.1159/000453207.
- Wu R, Zhu Z, Zhou D. VEGF, apelin and HO-1 in diabetic patients with retinopathy: a correlation analysis. Bmc Ophthalmol. 2020;20:326. doi:10.1186/s12886-020-01593-9.
- Niranjan G, Srinivasan AR, Srikanth K, et al. Evaluation of circulating plasma VEGF-A, ET-1 and magnesium levels as the predictive markers for proliferative diabetic retinopathy. Indian J Clin Bioche. 2018;34:1–05.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336–341. doi:10.1016/j.ijsu.2010.02.007.
- Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–536. doi:10.7326/0003-4819-155-8-201110180-00009.
- Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58:882–893. doi:10.1016/j.jclinepi.2005.01.016.
- Wang MF, Wang RF, Liu Y, Li X. Clinical application of four endothelial function indicators in diabetic retinopathy. Int Eye Sci. 2016;17:110–112.
- He N, Li B, Chen WW. Critical value of serum haemoglobinA1C, connective tissue growth factor, vascular endothelial growth factor and interleukin-6 in diabetic patient with diabetic retinopathy. Chin J Health Lab Tec. 2017;27:2663–2669.
- Zheng HD, Yu JX, Tian NY, Wu JM. Expression and significance of miR-126 and VEGF in proliferative diabetic retinopathy. J Chinese Physician. 2018;20:1447–1481.
- Chen JZ, Xian WG, Fu XL, He FT. Changes of serum vascular endothelial growth factor, apelin and heme oxygenase-1 levels in patients with type 2 diabetes mellitus and their relationship with diabetic retinopathy. Chin J Ocul Fundus Dis. 2019;35:145–149.
- Li JJ, Gu L, Jiang LL, Mu T. The expression and correlation of VEGF, ET, NO and AT-III in diabetic retinopathy. J Xinjiang Med Univ. 2019;42:346–350.
- Gu P, Mi GQ, Meng HY, Li JW, Chen HY. Predictive value of serum RBP4, β2-MG and VEGF levels for type 2 diabetic retinopathy. J N Sichuan Med Coll. 2021;36:449–453.
- FlynnJr HW, Schwartz SG, Scott IU. Emerging drugs for diabetic macular edema. Expert Opin Emerg Dr. 2014;19:397–405. doi:10.1517/14728214.2014.938048.
- Quan D, Brown D, Marcus D, Boyer D, Ehrlich JS. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. doi:10.1016/j.ophtha.2011.12.039.
- Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Db Syst Rev. 2017;6:D7419.
- Keles A, Sonmez K, Erol YO, Ayyıldız SN, Ogus E. Vitreous levels of vascular endothelial growth factor, stromal cell-derived factor-1α, and angiopoietin-like protein 2 in patients with active proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2021;259:53–60. doi:10.1007/s00417-020-04889-0.
- Liu R, Liu CM, Cui LL, Zhou L, Li N, Wei XD. Expression and significance of MiR-126 and VEGF in proliferative diabetic retinopathy. Eur Rev Med Pharmaco. 2019;23:6387–6393.
- Loporchio DF, Tam EK, Cho J, et al. Cytokine levels in human vitreous in proliferative diabetic retinopathy. Cells. 2021;10:1069. doi:10.3390/cells10051069.